Houzhen Tuo

Prof. Dr. Houzhen Tuo

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2022 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
YDYitong Du
Yitong Du
YLYue Li
Yue Li
XXXiaojiao Xu
Xiaojiao Xu
RLRongxue Li
Rongxue Li
MZMingkai Zhang
Mingkai Zhang
HTHouzhen Tuo
Houzhen Tuo

6 November 2024 in Chinese Medical Journal
Verified
Journal Article
Open access
LWLin Wang
Lin Wang
YCYing Cui
Ying Cui
BHBingyu Han
Bingyu Han
YDYitong Du
Yitong Du
KSKenish Sirajbhai Salewala
Kenish Sirajbhai Salewala
HTHouzhen Tuo
Houzhen Tuo
Emerging evidence suggests that dysbiosis of the gut microbiota is associated with the pathogenesis of Parkinson’s disease (PD), a prevalent neurodegenerative disorder. The microbiota–gut–brain axis plays a crucial role in the development and progression of PD, and numerous studies have demonstrated the potential therapeutic benefits of modulations in the intestinal microbiota. This review provides insights into the characterization of the gut microbiota in patients with PD and highlights associations with clinical symptoms and underlying mechanisms. The discussion underscores the increased influence of the gut microbiota in the pathogenesis of PD. While the relationship is not fully elucidated, existing research demonstrates a strong correlation between changes in the composition of gut microbiota and disease development, and further investigation is warranted to explain the specific underlying mechanisms.

27 July 2025 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
YDYitong Du
Yitong Du
LWLin Wang
Lin Wang
YCYing Cui
Ying Cui
XXXiaojiao Xu
Xiaojiao Xu
MZMingkai Zhang
Mingkai Zhang
HTHouzhen Tuo
Houzhen Tuo
Background: Parkinson's disease (PD) patients experience gut microbiota dysbiosis. Probiotic intervention could potentially serve as a safe and effective adjunctive therapeutic approach for PD, but its effects on rapid eye movement sleep behavior disorder (RBD) and motor symptoms in PD patients warrant further investigation.Objectives: To examine the influence of probiotics on RBD, motor symptoms, gut microbiota, and serum metabolites in individuals with PD.Methods: In this randomized controlled trial, PD patients were randomly allocated to either a probiotics or a control group while maintaining standard treatments. Clinical outcomes, including Unified Parkinson's Disease Rating Scale (UPDRS) and RBD Questionnaire‐Hong Kong (RBDQ‐HK) were assessed at baseline and post‐treatment. Furthermore, fecal and blood samples were collected from PD patients at both timepoints, with additional samples obtained from healthy controls for comparison. The 16S rRNA gene V3‐V4 region sequencing method was used to analyze gut microbiota composition, and untargeted metabolomic techniques were utilized to assess serum metabolite alterations, followed by correlation analysis.Results: Fifty eligible PD patients were enrolled and randomly allocated into two groups. After 12 weeks of intervention, the probiotic group showed significant reductions in both UPDRS total scores (−4.8 ± 7.5 vs. 1.8 ± 13.1, p = 0.009) and RBDQ‐HK scores (−7.5 ± 6.5 vs. 0 ± 5.8, p = 0.015) compared to controls. Gut microbiota analysis revealed increased abundance of Actinobacteria, Negativicutes, and Bacillus, with reductions in Lactococcus, Comamonas, and Enterococcus after probiotic intervention. Furthermore, compared to normal controls, PD patients exhibited 9 significantly elevated and 11 significantly reduced metabolites; probiotic intervention altered the serum metabolome in PD patients.Conclusions: This study demonstrated probiotics' potential to ameliorate RBD and motor symptoms while positively affecting the composition of the gut microbiota and serum metabolites in PD patients.

27 February 2024 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
XWXuan Wei
Xuan Wei
SWShiya Wang
Shiya Wang
MZMingkai Zhang
Mingkai Zhang
YYYing Yan
Ying Yan
ZWZheng Wang
Zheng Wang
ZWZhenchang Wang
Zhenchang Wang
Microstructural alterations in the brain networks of Parkinson’s disease (PD) patients are correlated with gait impairments. Evaluate microstructural alterations in the white matter (WM) fiber bundle tracts using neurite orientation dispersion and density imaging (NODDI) technique in PD versus healthy controls (HC). In this study, 24 PD patients and 29 HC were recruited. NODDI and high-resolution 3D structural images were acquired for each participant. The NODDI indicators, including the intracellular neurite density index (NDI), orientation dispersion index (ODI), and isotropic volume fraction (ISO), were compared between the two groups. Diffusion-weighted (DW) images were preprocessed using MRtrix 3.0 software and the orientation distribution function to trace the main nerve fiber tracts in PD patients. Quantitative gait and clinical assessment scales were used to compare the medication “ON” and “OFF” states of PD patients. The NDI, ODI, and ISO values of the WM fiber bundles were significantly higher in PD patients compared to HC. Fiber bundles, including the anterior thalamic radiation, corticospinal tract, superior longitudinal fasciculus, forceps major, cingulum, and inferior longitudinal fasciculus, were found to be significantly affected in PD. The NDI changes of PD patients were well correlated with stride lengths in the “ON” state; ODI changes were correlated with the stride time in the “ON” and “OFF” states and ISO changes were correlated with the stride time and cadence in the “ON” state. In conclusion, combination of NODDI technique and gait parameters can help detect gait impairment in PD patients early and accurately.

1 January 2020 in Nature and Science of Sleep
Verified
Journal Article
Open access
PDF file
LZLi-Yan Zhang
Li-Yan Zhang
XMXiao-Yang Ma
Xiao-Yang Ma
JLJun Lin
Jun Lin
WLWen-Hu Liu
Wen-Hu Liu
WGWang Guo
Wang Guo
HTHouzhen Tuo
Houzhen Tuo
Objective: The current study aimed to investigate the prevalence and risk factors of restless legs syndrome (RLS) in patients undergoing hemodialysis, as well as the mortality and risks of cardiovascular and cerebrovascular events. Methods: A total of 354 hemodialysis patients from four hospitals were enrolled. RLS was diagnosed using the International RLS Study Group (IRLSSG) criteria. The patients were evaluated face-to-face using the IRLSSG rating scale, Epworth Sleepiness Scale (ESS), Hamilton Anxiety Scale, Hamilton Depression Scale, and Pittsburgh Sleep Quality Index (PSQI). The patients were followed up for 9 months. Death was considered an endpoint event. The cardiovascular and cerebrovascular events were investigated. Results: The prevalence of RLS in hemodialysis patients was 40.7% and was associated with factors such as duration of hemodialysis, hypersensitive C-reactive protein, hyperparathyroidism, glycosylated serum protein, and erythropoietin treatment. The scores of the PSQI, ESS, and Hamilton Depression Scale in the RLS group were significantly higher than those in the non-RLS group (p < 0.05). During follow-ups, the incidence rate of cardiovascular diseases was 18.8% in the RLS group and 8.6% in the non-RLS group (p < 0.005). The IRLSSG rating scores were significantly higher in RLS patients with kidney transplantation failure compared with those without transplantation (p < 0.05). Conclusion: The prevalence of RLS was high in hemodialysis patients. The risk factors of RLS included duration of hemodialysis, hypersensitive C-reactive protein, hyperparathyroidism, glycosylated serum protein, and erythropoietin treatment. RLS affected sleep quality and emotion and increased the risk of cardiovascular diseases in hemodialysis patients. RLS was more severe in patients with kidney transplantation failure compared with those without transplantation.

1 January 2019 in Sleep Medicine
Verified
Journal Article
Closed access
HTHouzhen Tuo
Houzhen Tuo
ZTZelong Tian
Zelong Tian
XMXiaoyang Ma
Xiaoyang Ma
YCYinong Cui
Yinong Cui
YXYun Xue
Yun Xue
WOWilliam Ondo
William Ondo